India
· Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 192.06 billion. The enterprise value is 189.35 billion.
| Market Cap | 192.06B |
| Enterprise Value | 189.35B |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | Jun 21, 2024 |
Share Statistics
Concord Biotech has 104.62 million shares outstanding. The number of shares has decreased by -0.01% in one year.
| Shares Outstanding | 104.62M |
| Shares Change (YoY) | -0.01% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 50.26% |
| Owned by Institutions (%) | 10.89% |
| Float | 18.83M |
Valuation Ratios
The trailing PE ratio is 61.32 and the forward PE ratio is 46.82. Concord Biotech's PEG ratio is 1.72.
| PE Ratio | 61.32 |
| Forward PE | 46.82 |
| PS Ratio | 18.50 |
| PB Ratio | 12.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.72 |
Enterprise Valuation
| EV / Earnings | 60.45 |
| EV / Sales | 18.24 |
| EV / EBITDA | 42.29 |
| EV / EBIT | 48.00 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | n/a |
| Interest Coverage | 194.04 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 17.31% |
| Revenue Per Employee | 7.54M |
| Profits Per Employee | 2.27M |
| Employee Count | 1,377 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +82.40% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +82.40% |
| 50-Day Moving Average | 1,649.54 |
| 200-Day Moving Average | 1,503.94 |
| Relative Strength Index (RSI) | 67.90 |
| Average Volume (20 Days) | 285,099 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 10.38 billion and earned 3.13 billion in profits. Earnings per share was 29.94.
| Revenue | 10.38B |
| Gross Profit | 7.85B |
| Operating Income | 3.96B |
| Pretax Income | 4.21B |
| Net Income | 3.13B |
| EBITDA | 4.47B |
| EBIT | 3.96B |
| Earnings Per Share (EPS) | 29.94 |
Balance Sheet
The company has 2.82 billion in cash and 97.38 million in debt, giving a net cash position of 2.72 billion or 25.99 per share.
| Cash & Cash Equivalents | 2.82B |
| Total Debt | 97.38M |
| Net Cash | 2.72B |
| Net Cash Per Share | 25.99 |
| Equity (Book Value) | 15.27B |
| Book Value Per Share | 145.93 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 75.65%, with operating and profit margins of 38.13% and 30.18%.
| Gross Margin | 75.65% |
| Operating Margin | 38.13% |
| Pretax Margin | 40.57% |
| Profit Margin | 30.18% |
| EBITDA Margin | 43.10% |
| EBIT Margin | 38.13% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 8.75, which amounts to a dividend yield of 0.48%.
| Dividend Per Share | 8.75 |
| Dividend Yield | 0.48% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.01% |
| Shareholder Yield | 0.49% |
| Earnings Yield | 1.63% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |